Theracryf Plc
TCF.L · LSE
9/30/2025 | 3/31/2025 | 9/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | £4 | £862 | £35 | £5 |
| Gross Profit | -£4 | -£862 | -£35 | -£5 |
| % Margin | – | – | – | – |
| R&D Expenses | £0 | £398 | £0 | £1,736 |
| G&A Expenses | £0 | £0 | £0 | £0 |
| SG&A Expenses | £1,367 | £12 | £1,215 | £2,102 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | £0 | -£398 | £0 | -£1,736 |
| Operating Expenses | £1,367 | £12 | £1,215 | £2,102 |
| Operating Income | -£1,371 | -£874 | -£1,250 | -£2,107 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | £58 | £34 | £5 | £0 |
| Pre-Tax Income | -£1,313 | -£840 | -£1,245 | -£2,107 |
| Tax Expense | £0 | £144 | £0 | -£429 |
| Net Income | -£1,313 | -£696 | -£1,245 | -£1,678 |
| % Margin | – | – | – | – |
| EPS | 0 | -0.001 | -0.005 | -0.006 |
| % Growth | 100% | 75.6% | 26.2% | – |
| EPS Diluted | 0 | -0.001 | -0.005 | -0.006 |
| Weighted Avg Shares Out | 2,145,687 | 641,475 | 274,888 | 274,888 |
| Weighted Avg Shares Out Dil | 2,145,687 | 652,608 | 274,888 | 274,888 |
| Supplemental Information | – | – | – | – |
| Interest Income | £58 | £0 | £5 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £4 | £34 | £35 | £5 |
| EBITDA | -£1,309 | -£840 | -£1,210 | -£2,102 |
| % Margin | – | – | – | – |